Xanthelasma deposits on the eyelids are usually not accompanied by any subjective feelings and represent merely a cosmetic defect. Treatment in most cases is limited to the local direct impact on the lesion, without considering the mechanisms of xanthelasma formation, which are based on dyslipidemia of different genesis. Objectives. To study the effectiveness of the combination therapy uisng lipid-lowering drugs and the application of 20% trichloroacetic acid (TCA) on Xanthelasma-associated plaques. Material and methods. The study included 62 patients - 12 males (19.35%) and 50 females (80.65%) - aged 22-63, with different clinical manifestations of xanthelasmas. To investigate the lipid profile in patients, venous blood was taken after a 12-hour fasting followed by administration of lipid-lowering drugs. Local therapy consisted in application of 20% TCA directly onto the lesion area with a 21-day interval between the treatment courses. Results. When studying the lipid profile of blood, dyslipidemia was found in a number of patients. Dyslipidemia types IIa, IIb, III and hypo-alpha-lipoproteinemiya were detected in 38 (61.3%), 15 (24.2%), 3 (4.8%) and 2 (3.2%) patients, respectively. Patients with dyslipidemia received the lipid-lowering drug rosuvastatin (rosucard) 10 mg daily during 3 months. Effectiveness of the combination therapy was assessed according to elimination of clinical manifestations of the disease. It was found that one application was enough to heal the spotted form of xanthelasma. The plaque form required 3 single applications in 7 patients and 2 single drug administrations in the rest of patients. The procedure was repeated 3 times in all patients with papular xanthelasma. Cosmetic and therapeutic effects in patients with spotty, plaque and papular xanthelasmas were achieved in 100%, 93.5 % and 80% of cases, respectively. Conclusions. The use of combination therapy allowed us to achieve significant therapeutic and cosmetic effects after single or double-entry applications of 20% TCA with minimal fast transient side effects in 72.5% of cases. The proposed scheme was equally effective for treating all forms of eyelid xanthelasmas.